Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. News
  7. Summary
    OCGN   US67577C1053


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ocugen : Levi & Korsinsky, LLP

07/21/2021 | 12:46pm EDT

CLASS ACTION UPDATE for OCGN, RKT and BLCT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / July 21, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

OCGN Shareholders Click Here: https://www.zlk.com/pslra-1/ocugen-inc-information-request-form?prid=17846&wire=1
RKT Shareholders Click Here: https://www.zlk.com/pslra-1/rocket-companies-inc-loss-submission-form?prid=17846&wire=1
BLCT Shareholders Click Here: https://www.zlk.com/pslra-1/bluecity-holdings-limited-loss-submission-form?prid=17846&wire=1


Ocugen, Inc. (NASDAQ:OCGN)

OCGN Lawsuit on behalf of: investors who purchased February 2, 2021 - June 10, 2021
Lead Plaintiff Deadline : August 17, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ocugen-inc-information-request-form?prid=17846&wire=1

According to the filed complaint, during the class period, Ocugen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration (“FDA”) was insufficient to support an Emergency Use Authorization (“EUA”), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Rocket Companies, Inc. (NYSE:RKT)

RKT Lawsuit on behalf of: investors who purchased February 25, 2021 - May 5, 2021
Lead Plaintiff Deadline : August 30, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/rocket-companies-inc-loss-submission-form?prid=17846&wire=1

According to the filed complaint, during the class period, Rocket Companies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) Rocket's gain on sale margins were contracting at the highest rate in two years as a result of increased competition among mortgage lenders, an unfavorable shift toward the lower margin Partner Network operating segment and compression in the price spread between the primary and secondary mortgage markets; (b) Rocket was engaged in a price war and battle for market share with its primary competitors in the wholesale market, which was further compressing margins in Rocket's Partner Network operating segment; (c) the adverse trends identified above were accelerating and, as a result, Rocket's gain on sale margins were on track to plummet at least 140 basis points in the first six months of 2021; (d) as a result of the above, the favorable market conditions that had preceded the Class Period and allowed Rocket to achieve historically high gain on sale margins had vanished as the Company's gain on sale margins had returned to levels not seen since the first quarter of 2019; (e) rather than remaining elevated due to surging demand, Rocket's Company-wide gain-on-sale margins had fallen materially below recent historical averages; and (f) as a result of the foregoing, defendants' positive statements about the Company's business operations and prospects were materially misleading and/or lacked a reasonable basis.

Bluecity Holdings Limited (NASDAQ:BLCT)

This lawsuit is on behalf of all persons and entities, other than Defendants, who purchased or otherwise acquired BlueCity American Depositary Shares pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about July 8, 2020.
Lead Plaintiff Deadline : September 17, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bluecity-holdings-limited-loss-submission-form?prid=17846&wire=1

According to the filed complaint, (1) Defendants had overstated BlueCity's business and financial prospects; (2) the Company was ill-equipped to absorb the costs of becoming a publicly traded company, including IPO- and growth-related costs; (3) as a result of all the foregoing, Defendants had misrepresented the Company's capability for sustainable growth; and (4) as a result, the Offering Documents were materially false or misleading and/or failed to state information required to be stated therein.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com:


© Ritzau Denmark, source Ritzau English Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
OCUGEN, INC. -6.18% 7.44 Delayed Quote.306.56%
ROCKET COMPANIES, INC. -1.13% 16.59 Delayed Quote.-17.95%
All news about OCUGEN, INC.
09/17OCUGEN INC : . Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/17INSIDER SELL : Ocugen
09/16SOCIAL BUZZ : Wallstreetbets Stocks Largely in Negative Territory on Pre-Bell Th..
09/15OCUGEN, INC. : Regulation FD Disclosure (form 8-K)
09/14OCUGEN : Thinking about buying stock in FuelCell Energy, Farmmi, Aterian, Vinco ..
09/10OCUGEN INVESTIGATION INITIATED BY FO : Kahn Swick & Foti, LLC Investigates the O..
09/08OCUGEN, INC. : Other Events (form 8-K)
09/07OCUGEN : to Present at Upcoming Citi and H.C. Wainwright Investment Conferences
09/01EXPERT SERIES : The truth about COVID-19 variants
08/20OCUGEN INC : .áAnnounces Inducement Grants UnderáNasdaq Listing Rule 5635(c)(4)
More news
Analyst Recommendations on OCUGEN, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -55,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -26,0x
Yield 2021 -
Capitalization 1 479 M 1 479 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 10,9x
Nbr of Employees 15
Free-Float 97,5%
Duration : Period :
Ocugen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCUGEN, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 7,44 $
Average target price 7,90 $
Spread / Average Target 6,18%
EPS Revisions
Managers and Directors
Shankar Musunuri Chairman & Chief Executive Officer
Sanjay Subramanian CFO, Secretary & Head-Corporate Development
Arun Upadhyay Vice President-Research & Development
Bruce D. Forrest Chief Medical Officer
Uday B. Kompella Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OCUGEN, INC.306.56%1 479
MODERNA, INC.305.22%173 588
LONZA GROUP AG32.35%60 074
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-9.18%28 420